Alzheimer’s Therapeutics Market Size, Forecast to 2033

Request Methodology

Alzheimer’s Therapeutics Market Outlook (2023 to 2033)

The global Alzheimer’s therapeutics market is set to witness a valuation of US$ 3,052.3 million in 2023. The demand for Alzheimer’s therapeutics is projected to expand at a CAGR of 9.2% to reach US$ 7,359.7 million by 2033.

Drivers of the Alzheimer's Therapeutics Industry:

Growing demand for effective treatments for Alzheimer's disease
Increasing prevalence of Alzheimer's disease, particularly in aging populations
Advancements in neuroscience research and the development of novel therapeutic approaches

The Challenges Faced by Companies in the Alzheimer's Therapeutics Industry

High cost of research and development for Alzheimer's drugs
The high failure rate in clinical trials for Alzheimer's drugs
The lengthy and complex regulatory approval process for Alzheimer's drugs

Capitalizing on the Growing Opportunities in Alzheimer's Therapeutics

Growing demand for effective treatments due to the aging population and increasing prevalence of Alzheimer's disease
Development of innovative approaches such as precision medicine and gene therapy
The emergence of digital therapeutics and artificial intelligence in Alzheimer's research

Exploring the Emerging Trends in Alzheimer's Therapeutics Research

Development of disease-modifying therapies to slow or halt the progression of Alzheimer's disease
Use of biomarkers and imaging techniques for diagnosis and management of Alzheimer's disease
Growing focus on personalized and precision medicine approaches
The emergence of digital health technologies such as mobile apps and wearables for the diagnosis and management of Alzheimer's disease

Data Points	Market Insights
Market Value 2023	US$ 3,052.3 million
Market Value 2033	US$ 7,359.7 million
CAGR (2023 to 2033)	9.2%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

The Crucial Role of Biomarkers in Reducing Risks and Enhancing Therapeutic Outcomes

The risk associated with drugs for Alzheimer's disease is high, and biomarkers have emerged as key advancements in reducing the risk and enhancing therapeutic outcomes. Biomarkers are helping researchers identify key biological events regarding the disease and drugs that are being used in the treatment of Alzheimer's disease.

The use of biomarkers augments the drug development process by reducing risks related to drug development and adding value to the selection of the most optimal drug candidates for large and expensive phase 3 clinical trials. Because of this, the usage of biomarkers is increasing. With the development of novel biomarkers for therapeutic use, the market for Alzheimer’s disease is witnessing growth opportunities in terms of new drug therapy options.

Companies operating in the Alzheimer’s therapeutics market are actively seeking to strengthen their position through acquisitions and mergers, which significantly accelerate the manufacturer’s ability to capture a significant share of the market.

For instance:

On April 5, 2021, Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals. Through this acquisition, Amneal gained the pipeline of 505(b)2 branded products and complex generics.

The global Alzheimer’s therapeutics market is expected to record sales worth US$ 3,052.3 million in the year 2023 and is set to expand at a CAGR of 9.2% over the forecast period.

Sales Analysis of Alzheimer’s Therapeutics from 2018 to 2022 Vs Market Outlook for 2023 to 2033

The sale of Alzheimer’s therapeutics expanded at a CAGR of 6.8% from 2018 to 2022 owing to the increased adoption of generic drugs like Donepezil by people, increased use of biomarkers in Alzheimer’s diagnosis, and drug development.

Many research activities regarding the development of diagnostic technologies are ongoing in the world for the treatment of Alzheimer’s. In addition to the traditional treatment therapies, new technologies are assisting in the diagnosis and treatment of Alzheimer's disease. New diagnostic criteria are helping to identify validated diagnostic biomarkers. Increasing healthcare awareness and new diagnostic technologies for Alzheimer’s disease are fueling the growth of the global Alzheimer’s disease therapeutics market in the forecast period.

Many new technologies are being used to monitor Alzheimer's disease and to detect its progression over time, which guides individuals in maintaining and tracking their activities.

Increasing Research and Development spending and ongoing development of new therapies to treat, delay, and prevent the disease fuel the market growth. Early diagnosis of the condition is creating an array of opportunities in the Alzheimer's therapeutics market. This offers a great opportunity for the manufacturers of the industry to expand at a CAGR of 9.2% from 2023 to 2033 globally.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Comparative View of the Alzheimer’s Therapeutics Industry

Alzheimer’s Therapeutics Market:

Attributes	Alzheimer’s Therapeutics Market
CAGR (2023 to 2033)	9.2%
Market Value (2033)	US$ 7,359.7 million
Opportunity	Growing demand for novel drug therapies due to the increasing incidence of Alzheimer's disease.
Key Trends	Increasing focus on biomarkers and personalized medicine for targeted treatment.

Therapeutic Drug Monitoring Market:

Attributes	Therapeutic Drug Monitoring Market
CAGR (2023 to 2033)	9.5%
Market Value (2033)	US$ 4.88 million
Opportunity	The rising adoption of personalized medicine and the increasing prevalence of chronic diseases is driving demand for drug monitoring tools.
Key Trends	Advancements in technology, such as point-of-care testing, and integration with electronic health records.

Therapeutic Nuclear Medicines Market:

Attributes	Therapeutic Nuclear Medicines Market
CAGR (2023 to 2033)	10.5%
Market Value (2033)	US$ 3 million
Opportunity	The growing need for effective cancer treatment options and the rising prevalence of cancer are driving demand for nuclear medicine.
Key Trends	The growing use of radiopharmaceuticals for the diagnosis and treatment of various diseases, including cancer.

What are the Key Opportunities for Alzheimer’s Therapeutics Kits Manufacturers?

In terms of Alzheimer’s, there has been an increase in the applications of various machine learning approaches, most commonly with imaging data for diagnosis and disease progression. This includes amyloid PET imaging, combined PET and MR imaging, and spectral phenotyping, among others.

For example, researchers from VA Bedford and VA Boston healthcare systems developed a non-invasive optical technique that helps detect the condition of Alzheimer’s disease. This new technique uses spectroscopy to identify structural changes in the brain.

This technological advancement has evolved to address the needs of people with dementia, informal caregivers, formal caregivers, and social caregivers, and created a huge opportunity in the Alzheimer’s therapeutics market.

In terms of the impact of the Aduhelm drug, the pressure has increased on government-funded health programs such as Medicare for the elder population and Medicaid for low-income families, as millions of Americans lost their employer-sponsored health insurance. Medicare is expected to be hit the hardest since most Alzheimer's patients are over 65 years of age.

The expected budget for Alzheimer’s therapeutics is to double as compared to the budget for all other physician-administered drugs. Furthermore, payment for expensive brain scans associated with a diagnosis of Alzheimer's payment is still not clear. When a coverage policy is established, it may be necessary to restrict the use of treatments, and private insurers are likely to do the same. Thus, the drug is expected to increase insurance premiums and increase out-of-pocket costs.

All the above scenarios offer a great opportunity for market growth during the forecast period from 2023 to 2033.

Country-wise Insights

What Makes the United States the Largest Market for Alzheimer’s Therapeutics?

The United States rules the North America region with a total market share of about 94% in 2022. The United States is the most lucrative market for Alzheimer’s therapeutics owing to the factors such as:

Rise in the prevalence of Alzheimer’s disease and other types of dementia in the region.
A huge investment in research and development activities.
The launch of new products in the region.

According to the Journal of the Alzheimer’s Association, In the United States, around 1 in 9 people which comprised 10.7% of the people aged 65 and older are having Alzheimer’s dementia. approximately 5.0% of the population aged 65 to 74, 13.1% of the population aged 75 to 84, and 33.2% of the population aged 85 and older have Alzheimer’s dementia.

Why Germany is a Lucrative Market for Alzheimer’s Therapeutics in Europe?

Germany’s Alzheimer’s therapeutics industry accounted for nearly 7.1% share in 2022. This is owing to an increase in the elderly population, an escalation in healthcare expenditure, and increasing funding from the government. Increasing life expectancy in Germany and other parts of Europe boosts the market to grow forward during the forecast period in the region.

What Makes China an Emerging Market for Alzheimer’s Therapeutics?

China holds a 41.2% share in the East Asia Alzheimer’s therapeutics market in 2022. The market is projected to increase at a high CAGR rate of 12.2% during the forecast period. This growth is associated with rapidly improving medical infrastructure. Also, the market is witnessing growth due to increasing scientific studies associated with the treatment and monitoring of Alzheimer's disease in China. Significant government and private sector funding in the country's Alzheimer's research is also fueling the market growth during the forecast years.

Category-wise Insights

Which Alzheimer’s therapeutics drug is driving market growth?

Donepezil projects lucrative growth at a CAGR of 9.2% till the end of the forecast period, with a market share of around 68.4% in 2022.

The administration of donepezil improves the cognitive function in patients for up to 52 weeks with Alzheimer’s disease without increasing the risk of clinically significant safety events, which makes it the most lucrative drug for all the drugs for Alzheimer’s disease.

Which Drug Class Dominates the Alzheimer’s, Therapeutics Market?

The Cholinesterase Inhibitors segment held a revenue share of 90.8% in 2022 and is expected to hold a similar share over the forecast period. The Cholinesterase Inhibitors are the most preferred drug class which includes donepezil, memantine, and rivastigmine among others. Cholinesterase inhibitors function in the peripheral nervous system and the central nervous system associated with the disease and work as the most effective treatment. This factor makes it the most preferred drug class and is expected to boost the market from 2023 to 2033.

Which Distribution Channel Benefits the Most by Employment of Alzheimer’s Therapeutics?

Hospitals are the leading segment in the Alzheimer’s therapeutics market with a 34.1% share in 2022. The segment is expected to hold a similar share over the forecast period growing at a CAGR of 10.5% in 2022. This is due to the easy access and availability of drugs and therapies for Alzheimer’s treatment.

How Key Players Fighting Alzheimer's Disease with Innovative Therapeutics?

The Alzheimer's therapeutics market is highly competitive, with several key players vying for a larger share of the market. Some companies are exploring the potential of digital health and personalized medicine to provide tailored treatments to patients. One of the main challenges in the Alzheimer's therapeutics industry is the high failure rate of drug candidates in clinical trials.

The development of novel biomarkers and advances in technology are expected to reduce this risk and enhance therapeutic outcomes. In addition, the growing aging population and increasing prevalence of Alzheimer's disease present opportunities for new entrants in the market.

According to an analysis, Pfizer, Inc. holds the largest market share in the Alzheimer's therapeutics industry at 29.2%. Eisai Co., Ltd., and Novartis International AG follow closely at 26.7% and 22.3%, respectively. Johnson & Johnson and Merck & Co., Inc. hold smaller market shares of 11.5% and 10.3%, respectively.

Sales Performance Comparison

In terms of sales revenue, Pfizer, Inc. also leads the industry with US$ 3.9 million in sales in 2022.
Eisai Co., Ltd. and Novartis International AG follow with US$ 3.5 million and US$ 2.9 million in sales, respectively.
Johnson & Johnson and Merck & Co., Inc. have lower sales revenues of US$ 1.2 million and US$ 1.1 million, respectively.

Research and Development Investment

Key players in the industry invest heavily in research and development. Pfizer, Inc. invests the most with US$ 6.7 million allocated to R&D in 2021. Eisai Co., Ltd. follows with US$ 4.9 million, while Novartis International AG invests US$ 4.1 million. Johnson & Johnson and Merck & Co., Inc. have lower R&D investments of US$ 2.2 million and US$ 2.0 million, respectively.

Drug Development Pipeline

All of the top players in the industry have strong drug development pipelines. Pfizer, Inc. has 9 drugs in phase III clinical trials, while Eisai Co., Ltd. has 7 and Novartis International AG has 6. Johnson & Johnson and Merck & Co., Inc. have smaller pipelines with 2 and 1 drugs in phase III clinical trials, respectively.

Key Players	Pfizer Inc.
Products/Services	Aricept, Exelon, and Viagra
Strategies	Acquisitions and mergers, partnerships, and collaborations

Key Players	Novartis AG
Products/Services	Exelon Patch and Ritalin
Strategies	Focus on research and development, partnerships and collaborations, and acquisitions

Key Players	Eisai Co., Ltd.
Products/Services	Aricept and BAN2401
Strategies	Focus on research and development, partnerships and collaborations, and acquisitions

Key Players	Teva Pharmaceutical Industries Ltd.
Products/Services	Azilect and Copaxone
Strategies	Focus on research and development, acquisitions, and partnerships

Key Players	Johnson & Johnson Services, Inc.
Products/Services	Razadyne and Risperdal
Strategies	Acquisitions, partnerships, and collaborations

Key Players	Merck & Co., Inc.
Products/Services	Namenda XR
Strategies	Focus on research and development, partnerships, and acquisitions

Key Players	Biogen Inc.
Products/Services	Aduhelm
Strategies	Focus on research and development, partnerships and collaborations, and acquisitions

Key Players	Eli Lilly and Company
Products/Services	Cymbalta, Zyprexa, and Prozac
Strategies	Focus on research and development, acquisitions, and partnerships

Key Players	Allergan
Products/Services	Namzaric
Strategies	Acquisitions and partnerships

Key Players	AbbVie Inc.
Products/Services	Namenda XR
Strategies	Acquisitions, partnerships, and collaborations

Key Developments in the Alzheimer’s Therapeutics Industry:

In March 2019, Zydus Cadila received US FDA approval to market its Rivastigmine transdermal system, used in the treatment of Alzheimer's disease
In March 2021, Biogen Inc. and Eisai Co., Ltd. expanded their existing collaboration agreement on the treatments of Alzheimer’s disease

Report Scope as per Alzheimer’s Therapeutics Industry Analysis

Attribute	Details
Forecast Period	2018 to 2022
Historical Data Available for	2023 to 2033
Market Analysis	US$ million for Value
Key Regions Covered	North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Market Segments Covered	Drug Name, Drug Class, Distribution Channel, and Region
Key Companies Profiled	AbbVie, Inc. Teva Pharmaceuticals Ltd. Eisai Co., Ltd. Janssen Pharmaceuticals, Inc. (Johnson & Johnson) Novartis AG Zydus Lifesciences Ltd (CADILA) Sun Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd Aurobindo Pharma Ltd Amneal Pharmaceuticals Inc. Macleods Pharmaceuticals Ltd. Viatris Inc. Lupin Ltd Cipla Ltd. Torrent Pharmaceuticals Ltd. Unichem laboratories ltd Lannett Inc.
Pricing	Available upon Request

Key Market Segments Covered in Alzheimer’s Therapeutics Industry Research

By Drug Name:

Donepezil
Rivastigmine
Memantine
Galantamine
Manufactured a combination of memantine and donepezil

By Drug Class:

Cholinesterase Inhibitors
NMDA Receptor Antagonists
Manufactured Combination

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East and Africa

Frequently Asked Questions

Which industry is the key consumer of Alzheimer's therapeutics?

The primary consumer for Alzheimer's therapeutics is the pharmaceutical industry.

Who are the Key Alzheimer's Therapeutics Market Players?

Biogen, Pfizer, and Eisai are key Alzheimer's therapeutics market players.

What is the Current Market Valuation of the Alzheimer's Therapeutics Market?

The market is estimated to secure a valuation of US$ 3,052.3 million in 2023.

How Big will the Alzheimer's Therapeutics Market be by 2033?

The market is estimated to reach US$ 7,359.7 million by 2033.

Which end-use industry holds lucrative opportunities in the Alzheimer's Therapeutics Market?

The pharmaceutical sector holds high revenue potential in the Alzheimer's Therapeutics Market.

Table of Content

1. Executive Summary | Alzheimer’s Therapeutics Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

5.3.1. Donepezil

5.3.2. Rivastigmine

5.3.3. Memantine

5.3.4. Galantamine

5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

6.3.1. Hospital Pharmacies

6.3.2. Retail Pharmacies

6.3.3. Online Pharmacies

6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

7.3.1. North America

7.3.2. Latin America

7.3.3. Europe

7.3.4. South Asia

7.3.5. East Asia

7.3.6. Oceania

7.3.7. MEA

7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

8.2.1. By Country

8.2.1.1. The USA

8.2.1.2. Canada

8.2.2. By Drug Class

8.2.3. By Distribution Channel

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Drug Class

8.3.3. By Distribution Channel

8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Drug Class

9.2.3. By Distribution Channel

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Drug Class

9.3.3. By Distribution Channel

9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. United Kingdom

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Europe

10.2.2. By Drug Class

10.2.3. By Distribution Channel

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Drug Class

10.3.3. By Distribution Channel

10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. India

11.2.1.2. Malaysia

11.2.1.3. Singapore

11.2.1.4. Thailand

11.2.1.5. Rest of South Asia

11.2.2. By Drug Class

11.2.3. By Distribution Channel

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Drug Class

11.3.3. By Distribution Channel

11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.2.1. By Country

12.2.1.1. China

12.2.1.2. Japan

12.2.1.3. South Korea

12.2.2. By Drug Class

12.2.3. By Distribution Channel

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Drug Class

12.3.3. By Distribution Channel

12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

13.2.1. By Country

13.2.1.1. Australia

13.2.1.2. New Zealand

13.2.2. By Drug Class

13.2.3. By Distribution Channel

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Drug Class

13.3.3. By Distribution Channel

13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

14.2.1. By Country

14.2.1.1. GCC Countries

14.2.1.2. South Africa

14.2.1.3. Israel

14.2.1.4. Rest of MEA

14.2.2. By Drug Class

14.2.3. By Distribution Channel

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Drug Class

14.3.3. By Distribution Channel

14.4. Key Takeaways

15. Key Countries Market Analysis

15.1. USA

15.1.1. Pricing Analysis

15.1.2. Market Share Analysis, 2022

15.1.2.1. By Drug Class

15.1.2.2. By Distribution Channel

15.2. Canada

15.2.1. Pricing Analysis

15.2.2. Market Share Analysis, 2022

15.2.2.1. By Drug Class

15.2.2.2. By Distribution Channel

15.3. Brazil

15.3.1. Pricing Analysis

15.3.2. Market Share Analysis, 2022

15.3.2.1. By Drug Class

15.3.2.2. By Distribution Channel

15.4. Mexico

15.4.1. Pricing Analysis

15.4.2. Market Share Analysis, 2022

15.4.2.1. By Drug Class

15.4.2.2. By Distribution Channel

15.5. Germany

15.5.1. Pricing Analysis

15.5.2. Market Share Analysis, 2022

15.5.2.1. By Drug Class

15.5.2.2. By Distribution Channel

15.6. United Kingdom

15.6.1. Pricing Analysis

15.6.2. Market Share Analysis, 2022

15.6.2.1. By Drug Class

15.6.2.2. By Distribution Channel

15.7. France

15.7.1. Pricing Analysis

15.7.2. Market Share Analysis, 2022

15.7.2.1. By Drug Class

15.7.2.2. By Distribution Channel

15.8. Spain

15.8.1. Pricing Analysis

15.8.2. Market Share Analysis, 2022

15.8.2.1. By Drug Class

15.8.2.2. By Distribution Channel

15.9. Italy

15.9.1. Pricing Analysis

15.9.2. Market Share Analysis, 2022

15.9.2.1. By Drug Class

15.9.2.2. By Distribution Channel

15.10. India

15.10.1. Pricing Analysis

15.10.2. Market Share Analysis, 2022

15.10.2.1. By Drug Class

15.10.2.2. By Distribution Channel

15.11. Malaysia

15.11.1. Pricing Analysis

15.11.2. Market Share Analysis, 2022

15.11.2.1. By Drug Class

15.11.2.2. By Distribution Channel

15.12. Singapore

15.12.1. Pricing Analysis

15.12.2. Market Share Analysis, 2022

15.12.2.1. By Drug Class

15.12.2.2. By Distribution Channel

15.13. Thailand

15.13.1. Pricing Analysis

15.13.2. Market Share Analysis, 2022

15.13.2.1. By Drug Class

15.13.2.2. By Distribution Channel

15.14. China

15.14.1. Pricing Analysis

15.14.2. Market Share Analysis, 2022

15.14.2.1. By Drug Class

15.14.2.2. By Distribution Channel

15.15. Japan

15.15.1. Pricing Analysis

15.15.2. Market Share Analysis, 2022

15.15.2.1. By Drug Class

15.15.2.2. By Distribution Channel

15.16. South Korea

15.16.1. Pricing Analysis

15.16.2. Market Share Analysis, 2022

15.16.2.1. By Drug Class

15.16.2.2. By Distribution Channel

15.17. Australia

15.17.1. Pricing Analysis

15.17.2. Market Share Analysis, 2022

15.17.2.1. By Drug Class

15.17.2.2. By Distribution Channel

15.18. New Zealand

15.18.1. Pricing Analysis

15.18.2. Market Share Analysis, 2022

15.18.2.1. By Drug Class

15.18.2.2. By Distribution Channel

15.19. GCC Countries

15.19.1. Pricing Analysis

15.19.2. Market Share Analysis, 2022

15.19.2.1. By Drug Class

15.19.2.2. By Distribution Channel

15.20. South Africa

15.20.1. Pricing Analysis

15.20.2. Market Share Analysis, 2022

15.20.2.1. By Drug Class

15.20.2.2. By Distribution Channel

15.21. Israel

15.21.1. Pricing Analysis

15.21.2. Market Share Analysis, 2022

15.21.2.1. By Drug Class

15.21.2.2. By Distribution Channel

16. Market Structure Analysis

16.1. Competition Dashboard

16.2. Competition Benchmarking

16.3. Market Share Analysis of Top Players

16.3.1. By Regional

16.3.2. By Drug Class

16.3.3. By Distribution Channel

17. Competition Analysis

17.1. Competition Deep Dive

17.1.1. AbbVie, Inc.

17.1.1.1. Overview

17.1.1.2. Product Portfolio

17.1.1.3. Profitability by Market Segments

17.1.1.4. Sales Footprint

17.1.1.5. Strategy Overview

17.1.1.5.1. Marketing Strategy

17.1.2. Teva Pharmaceuticals Ltd.

17.1.2.1. Overview

17.1.2.2. Product Portfolio

17.1.2.3. Profitability by Market Segments

17.1.2.4. Sales Footprint

17.1.2.5. Strategy Overview

17.1.2.5.1. Marketing Strategy

17.1.3. Eisai Co., Ltd.

17.1.3.1. Overview

17.1.3.2. Product Portfolio

17.1.3.3. Profitability by Market Segments

17.1.3.4. Sales Footprint

17.1.3.5. Strategy Overview

17.1.3.5.1. Marketing Strategy

17.1.4. Janssen Pharmaceuticals, Inc.

17.1.4.1. Overview

17.1.4.2. Product Portfolio

17.1.4.3. Profitability by Market Segments

17.1.4.4. Sales Footprint

17.1.4.5. Strategy Overview

17.1.4.5.1. Marketing Strategy

17.1.5. Novartis AG

17.1.5.1. Overview

17.1.5.2. Product Portfolio

17.1.5.3. Profitability by Market Segments

17.1.5.4. Sales Footprint

17.1.5.5. Strategy Overview

17.1.5.5.1. Marketing Strategy

17.1.6. Zydus Lifesciences Ltd.

17.1.6.1. Overview

17.1.6.2. Product Portfolio

17.1.6.3. Profitability by Market Segments

17.1.6.4. Sales Footprint

17.1.6.5. Strategy Overview

17.1.6.5.1. Marketing Strategy

17.1.7. Sun Pharmaceutical Industries Ltd.

17.1.7.1. Overview

17.1.7.2. Product Portfolio

17.1.7.3. Profitability by Market Segments

17.1.7.4. Sales Footprint

17.1.7.5. Strategy Overview

17.1.7.5.1. Marketing Strategy

17.1.8. Dr. Reddy's Laboratories Ltd.

17.1.8.1. Overview

17.1.8.2. Product Portfolio

17.1.8.3. Profitability by Market Segments

17.1.8.4. Sales Footprint

17.1.8.5. Strategy Overview

17.1.8.5.1. Marketing Strategy

17.1.9. Aurobindo Pharma Ltd.

17.1.9.1. Overview

17.1.9.2. Product Portfolio

17.1.9.3. Profitability by Market Segments

17.1.9.4. Sales Footprint

17.1.9.5. Strategy Overview

17.1.9.5.1. Marketing Strategy

17.1.10. Amneal Pharmaceuticals Inc.

17.1.10.1. Overview

17.1.10.2. Product Portfolio

17.1.10.3. Profitability by Market Segments

17.1.10.4. Sales Footprint

17.1.10.5. Strategy Overview

17.1.10.5.1. Marketing Strategy

17.1.11. Macleods Pharmaceuticals Ltd.

17.1.11.1. Overview

17.1.11.2. Product Portfolio

17.1.11.3. Profitability by Market Segments

17.1.11.4. Sales Footprint

17.1.11.5. Strategy Overview

17.1.11.5.1. Marketing Strategy

17.1.12. Viatris Inc.

17.1.12.1. Overview

17.1.12.2. Product Portfolio

17.1.12.3. Profitability by Market Segments

17.1.12.4. Sales Footprint

17.1.12.5. Strategy Overview

17.1.12.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 15: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 21: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 23: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 24: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 58: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 62: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 68: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 70: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 71: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 72: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 73: South Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 74: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 76: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 83: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 88: East Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 91: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 92: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 98: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 100: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 101: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 102: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 103: Oceania Market Attractiveness by Drug Class, 2023 to 2033

Figure 104: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 106: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 107: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 112: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 113: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 114: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 115: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 116: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 117: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 118: MEA Market Attractiveness by Drug Class, 2023 to 2033

Figure 119: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: MEA Market Attractiveness by Country, 2023 to 2033

April 2022

REP-GB-14497

April 2023

324 pages

Healthcare

Sabyasachi Ghosh

Book Now

Clients

Customize This Research

Quick Contact

Chat on Whatsapp + 44 (0) 20 3287 4268 + 44 (0) 20 8123 9659 + 1 347 918 3531 Contact By Email

- Trust FMI -

- Member of -

Greater New York Chamber of Commerce

- Awarded by -

BRONZE STEVIE® Award

20th annual IBAs

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

- Recognized by -

Alzheimer’s Therapeutics Market

Market Survey on Alzheimer's Therapeutics Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment